TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through the Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It off… Read more
TTY Biopharm Co Ltd (4105) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.038x
Based on the latest financial reports, TTY Biopharm Co Ltd (4105) has a cash flow conversion efficiency ratio of 0.038x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$263.87 Million) by net assets (NT$6.93 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TTY Biopharm Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how TTY Biopharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TTY Biopharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TTY Biopharm Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Head Co Ltd
SHE:002810
|
0.028x |
|
Keshun Waterproof Technologies Co Ltd Class A
SHE:300737
|
-0.058x |
|
Zhuzhou Tianqiao Crane Co Ltd
SHE:002523
|
0.041x |
|
Carabao Group Public Company Limited
BK:CBG-R
|
0.092x |
|
ITOCHU ENEX
F:96P
|
N/A |
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
N/A |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
-0.127x |
|
Hagerty Inc
NYSE:HGTY
|
0.129x |
Annual Cash Flow Conversion Efficiency for TTY Biopharm Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of TTY Biopharm Co Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$7.51 Billion | NT$1.35 Billion | 0.180x | +7.70% |
| 2023-12-31 | NT$6.51 Billion | NT$1.09 Billion | 0.167x | -15.86% |
| 2022-12-31 | NT$6.23 Billion | NT$1.24 Billion | 0.198x | -8.99% |
| 2021-12-31 | NT$5.77 Billion | NT$1.26 Billion | 0.218x | +151.55% |
| 2020-12-31 | NT$6.08 Billion | NT$526.35 Million | 0.087x | -55.84% |
| 2019-12-31 | NT$6.17 Billion | NT$1.21 Billion | 0.196x | +16.74% |
| 2018-12-31 | NT$6.39 Billion | NT$1.07 Billion | 0.168x | +3.03% |
| 2017-12-31 | NT$6.11 Billion | NT$996.52 Million | 0.163x | -- |